Rennova Health, Inc. · OTC:RNVA
Rennova Health — Investor Presentation (January 2017)
20 slides from Rennova Health's investor presentation, January 2017
Slide 1: Diagnostics and Supportive Software Solutions to Healthcare Providers
January 2017 Nasdaq: RNVA, RNVAZ Diagnostics and Supportive Software Solutions to Healthcare Providers
Slide 2: Forward Looking Statements and Non-GAAP Information
Forward Looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova Health’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, obj
Slide 3: Healthcare is Being Transformed
Healthcare is Being Transformed We are Rennova Health 3
Slide 4: Key Investment Highlights
Key Investment Highlights • Five-year history of operations in clinical laboratory space and three years in software development for the medical sector • Capital investment in our Clinical Labs of approximately $8M • Own Labs in Florida, New Mexico, New Jersey, California and Connecticut • Adequate
Slide 5: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers • The diagnostics sector has changed dramatically in the last few years • Paper records and faxes meant different vendors to a medical provider could function side by side without communication • Electronic platforms and integration have
Slide 6: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers Clinical Lab Services 5 Clinical Laboratories Single Source Solution Revenue Software Cycle Solutions Management Proprietary Lab ordering and reporting Laboratory Information System (LIS) Integrated Medical Billing Company EHR / Practice
Slide 7: Recent Developments
Recent Developments Clinical Laboratory Operations Segment • We agreed to purchase Genomics, Inc. a biomedical diagnostics company that delivers personalized medicine by offering DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease and diabetes through a
Slide 8: Recent Developments
Recent Developments Supportive Software Solutions Segment • Our integrated software solution creates a much more sustainable relationship with our customers • EHR product launched in substance abuse sector last quarter 2015 • We believe we are on target to have secured approximately 100 EHR clients
Slide 9: Our Target Markets
Our Target Markets Drug and Alcohol Rehabilitation • Total Market Size – estimated at $35 Billion* • Large and growing number of facilities in a fragmented market • Between 14,500 to 16,700 outpatient clinics* Market growth from high demand: • Over 23 million Americans are addicted to alcohol and ot
Slide 10: Rennova Health Licensing Map
Rennova Health Licensing Map 10
Slide 11: Our Payers
Our Payers • Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015 o Applied for Medicaid Licenses in 34 States o As of December 7, 2016, we possess Medicaid Licenses in 28 States • Current Third Party Insurance Payer Contracts o Blue Shield of California o Fortified Provider
Slide 12: History in Numbers
History in Numbers ($000’s) 70,000 59,429 60,000 50,000 41,889 37,877 40,000 28,921 30,000 19,749 20,000 14,775 10,000 6,904 1,386 0 (315) (10,000) (20,000) (19,517) (30,000) 2013 2014 2015 9 Months 2015 9 Months 2016 Adjusted Revenues Adjusted EBITDA 12
Slide 13: Select Income Statement Items
Select Income Statement Items 9 Months 9 Months (in thousands) 2013 2014 2015 2015 2016 GAAP Net Revenue $ 41,889 $ 57,928 $ 18,393 $ 28,921 $ 5,223 Reserve for Aged Accounts Receivable - 1,501 19,494 - 1,681 Adjusted Revenues $ 41,889 $ 59,429 $ 37,887 $ 28,921 $ 6,904 GAAP Pretax Income (Loss) $ 1
Slide 14: Strategy
Strategy 14
Slide 15: The Long Term Strategy
The Long Term Strategy Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders How? Build from a toxicology-focused company to: 1. A significant and diverse diagnostics business 2. Offering supportive software solutions that add value by g
Slide 16: 2017 Goals
2017 Goals • Strengthen Core Diagnostic Business o Plan to open our 1st hospital and include detox facility and clinical lab capabilities o Continue to capitalize on the disruption in toxicology sector o Increase Clinical testing o Grow Pharmacogenomics testing with Genomas o Launch DTC (Direct to C
Slide 17: Rennova Management
Rennova Management Seamus Lagan • 20 years experience in the restructuring, development and CEO & Interim CFO management of startup and small companies Marc Gelberg, CPA • 20 years experience with public companies encompassing Director of Finance all aspects of financial management and SEC reporting
Slide 18: Board of Directors
Board of Directors • 20 years experience in the restructuring, development and Seamus Lagan management of startup and small companies CEO & Interim CFO • Founder, investor and shareholder • Chairman and CEO of Integrated Financial Settlements, Inc., a Christopher Diamantis structured settlement cons
Slide 19: Rennova Health, Inc. Capitalization Table
Rennova Health, Inc. Capitalization Table As of December 22, 2016 Common Shares Issuable upon Exercise/ Shares Outstanding Conversion Common Stock 58,111,261 58,111,261 Series G Preferred Stock 215 477,778 Series H Preferred Stock 12,350 137,222,222 Convertible Debt 1,760,000 Underwriter's warrants
Slide 20: Key Investment Highlights
Key Investment Highlights • Five-year history of operations in clinical laboratory space and three years in software development for the medical sector • Capital investment in our Clinical Labs of approximately $8M • Own Labs in Florida, New Mexico, New Jersey, California and Connecticut • Adequate
Rennova Health — Investor Presentation (January 2017) on 6ix